Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products

Products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC2864 Jtk-853
Novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase
More description
DCC2863 Jte-607
Cytokine release inhibitor, inhibiting production of IL-1ß, IL-8, IL-6, IL-10 and TNFalpha
More description
DCC2862 Jte-151
Novel RORγ
More description
DCC2861 Jsi287
Novel ERK inhibitor, alleviating IMQ-induced mice skin lesions through ERK/IL-17 signaling pathway
More description
DCC2860 Jsf-2513
Novel potent antitubercular agent, inhibiting InhA and FAS-II pathway
More description
DCC2859 Jsf-2019
Novel antitubercular agent, inhibiting InhA and FAS-II pathway
More description
DCC2858 Js399-19
Novel specific inhibitor of Fusarium myosin I; Fungicide
More description
DCC2857 Jrc-ii-191
Novel inhibitor of CD4-gp120 binding, blocking the binding of the HIV-1 envelope glycoprotein gp120 to the CD4 receptor
More description
DCC2856 Jra-003
Novel selective inhibitor of nuclear translocation of IKKα as the most potent synthetic gibberellin against cancer-derived cell lines, displaying no cytotoxicity in cells derived from noncancerous sources (HEK 293T, HS 578BST, HS 888Lu, HS 895Sk, HUVEC)
More description
DCC2855 Jr-220
Non-toxic anti-relapse agent, acamprosate
More description
DCC2854 Jp4-039
Non-toxic radioprotector GS-nitroxide, improving hematopoiesis in long-term bone marrow cultures (LTBMCs)
More description
DCC2853 Jp1201
Novel SMAC mimetic, sensitizing non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner
More description
DCC2852 Jns 1-40
Novel cysteine-reactive covalent ligand, selectively targeting C377 of PPP2R1A to impair breast cancer signaling, proliferation, and in vivo tumor growth
More description
DCC2851 Jnj-dgat2-b
Selective DGAT2 inhibitor
More description
DCC2850 Jnj-dgat1-a
Selective DGAT1 inhibitor
More description
DCC2849 Jnj-61432059
Novel TARP γ-8 Selective AMPAR Negative Modulator
More description
DCC2848 Jnj-53721590
Negative control for JNJ-54119936
More description
DCC2847 Jnj-49153390
Novel inhibitor of respiratory syncytial virus (RSV), binding the RSV F glycoprotein and inhibiting membrane fusion
More description
DCC2846 Jnj-42491293
Novel ago-PAM for the metabotropic glutamate receptor subtype 2 (mGluR2)
More description
DCC2845 Jnj-42396302
Novel inhibitor of PDE10A
More description
DCC2844 Jnj-40929837
Novel potent, orally active LTA4H inhibitor
More description
DCC2843 Jnj-40573663
Negaive control for JNJ-42396302
More description
DCC2841 Jnj-40264796
Negative control for JNJ-40068782
More description
DCC2840 Jnj-40255293
Novel Adenosine A 2A /A 1 Antagonist With Efficacy In Preclinical Models of Parkinson's Disease
More description
DCC2839 Jnj-40068782
Novel potent, selective, and systemically active positive allosteric modulator (PAM) of mGlu2-receptors
More description
DCC2838 Jnj-28583867
Histamine H3 receptor antagonist and serotonin reuptake inhibitor
More description
DCC2837 Jnj-28330835
Selective androgen receptor modulator with minimal prostate hypertrophic activity stimulating sexual behavior in female rats
More description
DCC2836 Jnj-26076713
Novel EthR inhibitor, boosting antituberculous activity of ethionamide
More description
DCC2835 Jnj-20788560
Selective delta opioid receptor agonist as a potent and efficacious antihyperalgesic agent
More description
DCC2834 Jnj-1930942
Novel Positive Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X